Wachtell Kristian, Devereux Richard B, Lyle And Paulette A
Department of Cardiology B2142, Rigshospitalet, The Heart Center, 9 Blegdamsvej, DK-2100 Copenhagen, Denmark.
Curr Hypertens Rep. 2007 Aug;9(4):278-83. doi: 10.1007/s11906-007-0051-1.
Atrial fibrillation is the most common sustained cardiac arrhythmia in clinical practice, and causes significant burden to patients and health care systems. Clinicians treat existing atrial fibrillation with anticoagulation and/or drugs that utilize either a rate or rhythm control strategy. It remains unclear how best to reduce cardiovascular morbidity and mortality in this population. Prevention of atrial fibrillation using angiotensin receptor blockers, which affect ion currents and refractoriness in atrial myocytes, regress or prevent atrial fibrosis, decrease left atrial size, regress left ventricular hypertrophy, modulate sympathetic nerve activity, reduce inflammation, and reduce blood pressure, may become an important and desirable alternative.
心房颤动是临床实践中最常见的持续性心律失常，给患者和医疗保健系统带来了沉重负担。临床医生使用抗凝药物和/或采用心率或节律控制策略的药物来治疗现有的心房颤动。目前尚不清楚如何最好地降低这一人群的心血管发病率和死亡率。使用血管紧张素受体阻滞剂预防心房颤动可能成为一种重要且理想的替代方法，血管紧张素受体阻滞剂可影响心房肌细胞的离子电流和不应期、消退或预防心房纤维化、减小左心房大小、消退左心室肥厚、调节交感神经活动、减轻炎症并降低血压。
